Loading
A phase 2 trial of Resminostat in Hodgkin lymphoma, run by 4SC AG, completed.
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT01037478 by 4SC AG, with 37 participants recorded, started 2009-12 and reaching its primary completion in 2012-01. Interventions recorded: Resminostat (4SC-201). Conditions recorded: Hodgkin's Lymphoma.
Linked to the drug Resminostat because the registry names it among its interventions and Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares 4SC, Resminostat and the tag pipeline.
Shares 4SC, Resminostat and the tag pipeline.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/